CLINICAL TRIAL: HALT PKD

临床试验：停止 PKD

• 批准号: 7951199
• 负责人: FRANZ WINKLHOFER
• 金额: $ 23.8万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951199
• 关键词: Aldosterone; Angiotensins; Autosomal Dominant Polycystic Kidney; Chymosin; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Individual; Institution; Kidney Diseases; Research; Research Personnel; Resources; Source; Staging; System; United States National Institutes of Health; blood pressure regulation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the impact of intensive blockade of the rennin-angiotensin-aldosterone system (RAAS) and the level of blood pressure control on progressive renal disease in individuals with early and more advanced stages of autosomal dominant polycystic kidney disease.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是确定强化阻断肾素-血管紧张素-醛固酮系统（RAAS）和血压控制水平对患有早期和晚期常染色体显性多囊肾病的个体进行性肾病的影响。